Blood Screening Market to Cross 10% Annual Growth Rate to 2019 Says a Latest Research Report Available at RnRMarketResearch.com
(PRWEB) March 21, 2015 -- The blood screening market size is expected to reach $2.55 billion by 2019 from $1.5 billion in 2014, at a CAGR of 10.4%. This market is categorized on the basis of products and services, technologies, end users, and regions. On the basis of products and services, the blood screening market is categorized into instruments (hardware), reagents, and software and services. The reagents segment accounted for the largest share of the blood screening market and is expected to grow at the highest CAGR in the coming five years. The increasing adoption rate of NAT, rising number of blood donations, disposable nature of reagents, and growing demand of blood for transfusion are driving the growth of this segment.
The World Health Organization (WHO) projects that 92 million blood donations are made every year that are possible entries for blood donor screening. Obviously, some of these are underdeveloped nations where MDx tests are not performed because of the low financial power and absence of testing tools. In the U.S. there are roughly 25 million blood and plasma donations and another 40-50 million donations in Europe, Japan and other industrialized nations.
Complete report is available at http://www.rnrmarketresearch.com/blood-screening-market-by-technology-nucleic-acid-amplification-test-elisa-rapid-test-chemiluminescence-immunoassay-next-generation-sequencing-western-blotting-product-instrument-reagent-market-report.html.
The Blood Screening Market will keep on experiencing the healthy growth rate for the rest of the decade. Infectious disease testing will remain an essential element in the development. Even without the addition of any new infectious disease tests, the industry will experience healthy and solid growth from continued decentralization of testing in smaller laboratories and geographic expansion into immature markets.
The major factors contributing to the growth of the blood screening market include an increasing number of blood donations and blood donors, increasing awareness regarding the safety of donated blood, increasing patient affordability, and increasing demand of donated blood. Furthermore, increasing adoption of NAT by governments of various countries is another major factor providing impetus for growth of this market. For instance, in 2014, the Japanese Red Cross entered into an agreement with Grifols (Spain) for nucleic acid testing (NAT) for the total blood donated in Japan. This agreement is expected to aid the growth of the blood screening market during the forecast period.
The companies profiled in blood screening market research report are Grifols, Roche Diagnostics (A Division of F. Hoffmann-La Roche Ltd), Abbott Laboratories, Biomérieux, Bio-Rad Laboratories, Inc., Siemens Healthcare (Subsidiary of Siemens AG), Ortho-Clinical Diagnostics, Inc., Thermo Fisher Scientific, Inc., Beckman Coulter (Subsidiary of Danaher Corporation), and Becton, Dickinson and Company.
Order a copy of this research report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=310626.
There will be restricted natural growth as the quantity of blood donations remains genuinely steady year to year in the major developed nations. Consequently, the important development opportunities in a blood donor screening segment are (i) move more research facilities to higher estimated full automation and (ii) alter to "home blend" and "non-analyzers" to government sanction IVD blood screening tests. The developing BRIC market may speak to the most guaranteed opportunity additional growth. As a fact, blood donations in China keep on growing and the regulatory authorities have ordered that all blood donations must be screened by using molecular technology by 2015.
Reasons to Buy Blood Screening Market by Technology (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product (Instrument, Reagent) & End User (Blood Bank, Hospital) – Forecasts to 2019Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms, garner a greater market share. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
This is a premium research report priced at US$ 4650 for single user PDF license, Inquire for discount on this research report @ http://www.rnrmarketresearch.com/contacts/discount?rname=310626.
Similar Reports:
“Isothermal Nucleic Acid Amplification Technology (INAAT) Market by Application (Infectious Diseases, Blood Screening, Research), Products (Instruments, Reagents), End-User (Hospital, Reference Laboratories, Other) – Global Forecast to 2018” is a May 2014 publication of 215 pages and it says Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market is poised to reach $1,651 million by 2018 at a CAGR of 13.5%. The increasing demand for enhanced molecular testing using INAAT as well as rising incidence of infectious diseases is driving market growth over the conventional thermal polymerase chain reaction (PCR) technology. Companies profiled in this research report are Alere, Becton, Dickinson and Company (BD), Biohelix, Biomerieux, Eiken Chemical Co., Ltd., Hologic Gen-Probe, Lucigen, Meridian Bioscience, Inc., New England Biolabs, Novartis Diagnostics, Nugen, Qiagen, and Ustar Biotechnologies (Hangzhou) Ltd. Complete report available at http://www.rnrmarketresearch.com/isothermal-nucleic-acid-amplification-technologies-market-2012-2017-molecular-diagnostics-infectious-disease-testing-blood-screening-cancer-research-rapid-testing-market-report.html.
“High Content Screening Market by Instruments (Cell Imaging and Analysis System), by Applications (Primary and Secondary Screening, Target Identification and Validation, Toxicity Studies, Compound Profiling), Software & Services – Global Forecasts to 2018” is a Feb 2014 publication of 151 pages and it says Global High Content Screening Market was valued at an estimated $362.2 million in 2013 and is expected to reach $615.8 million by 2018, growing at a CAGR of 11.2% from 2013 to 2018. Companies profiled in this research report are Becton, Dickinson and Company, Cell Signaling Technology, Inc., Danaher Corporation, GE Healthcare (Subsidiary of General Electric Company), Genedata AG, Merck Kgaa, Perkinelmer, Inc., Thermo Fisher Scientific, Inc., Thorlabs, Inc., and Yokogawa Electric Corporation. Complete report available at http://www.rnrmarketresearch.com/high-content-screening-market-by-instruments-cell-imaging-and-analysis-system-by-applications-primary-and-secondary-screening-target-identification-and-validation-toxicity-studies-compound-prof-market-report.html.
Explore more research report on ‘Life Sciences Market’ @ http://www.rnrmarketresearch.com/reports/life-sciences.
About us:
RnR Market Research library offers syndicated reports by market research publishers from across the globe. We help you find the most relevant business intelligence from ready-to-buy syndicated market research studies. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more, RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest. (http://www.rnrmarketresearch.com/market-research-reports-publisher).
Siju K., RnRMarketResearch.com, http://www.rnrmarketresearch.com/, +1 (888) 391-5441, [email protected]
Share this article